Novartis : Q4 2023 results and 2024 guidance a shade below expectations
>Q4 2023 results disappointing on bottom line - Q4 sales (-1% vs consensus) and core EPS (-4% vs consensus) were slightly below expectations. Sales rose by 10% cc (8% on a reported basis), driven by Entresto (+27%, +2% vs consensus), Cosentyx (+21%, +2% vs css), Kisqali (+71%, +1% vs css) and Kesimpta (+74%, +9% vs css). Note that Pluvicto (+53%, -13% vs css), in the launch phase, undershot expectations which is a disappointment for this quarter. The product should ne...Novartis is a multinational healthcare group based in Switzerland. Co. provides healthcare solutions that address the evolving needs of patients and societies worldwide. Co.'s broad portfolio includes innovative medicines, eye care products and cost-saving generic pharmaceuticals. Co.'s operations are organized along three operating divisions: Innovative Medicines Division; Sandoz Division; and Alcon Division. Co.'s operations are supported by the Novartis Institutes for BioMedical Research and Novartis Business Services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.